Sensus Healthcare Q2 2025 revenue $7.3M, net loss $1.0M; ships 19 SRT systems, FDA volume up 27% sequentially

Sensus Healthcare, Inc.

2025-Q2 EPS reported -$0.22 revenue$15,659,000

Revenue $7.3M vs $9.2M YoY; net loss $1.0M ($0.06/sh) vs net income $1.6M ($0.10/sh) in Q2 2024.
Shipped 19 SRT systems, including 4 to China; signed 5 new Fair Deal Agreements, 4 live; FDA volume +27% seq.
Gross margin fell to 39.7% from 58.7% on lower sales and higher service costs; adjusted EBITDA negative $1.8M.
Ended quarter with $22.2M cash and no debt; engaged Radiology Oncology Systems as distribution partner for hospitals.
Proposed Physician Fee Schedule expected to align outpatient SRT reimbursement with hospital rates starting Jan 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.